The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib

Kevin R. Kelly, Jeffrey Ecsedy, Ernest Medina, Devalingam Mahalingam, Swaminathan Padmanabhan, Steffan T. Nawrocki, Francis J. Giles, Jennifer S. Carew

Research output: Contribution to journal › Article › peer-review

71 Scopus citations

Fingerprint

Dive into the research topics of 'The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib'. Together they form a unique fingerprint.

Medicine & Life Sciences